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Abstract
The intermediate dose spill for a stereotactic radiosurgery (SRS) plan can be quanti-
fied with the metric R50%, defined as the 50% isodose cloud volume (VIDC50%)
divided by the volume of the planning target volume (PTV). By coupling sound phys-
ical principles with the basic definition of R50%, we derive an analytical expression
for R50% for a spherical PTV. Our analytical expression depends on three quantities:
the surface area of PTV (SAPTV), the volume of PTV (VPTV), and the distance of dose
drop-off to 50% (Δr). The value of Δr was obtained from a simple set of cranial
phantom plan calculations. We generate values from our analytical expression for
R50% (R50%Analytic) and compare the values to clinical R50% values (R50%Clinical)
extracted from a previously published SRS data set that spans the VPTV range from
0.15 to 50.1 cm3. R50%Analytic is smaller than R50%Clinical in all cases by an average
of 15%  7%, and the general trend of R50%Clinical vs VPTV is reflected in the same
trend of R50%Analytic. This comparison suggests that R50%Analytic could represent a
theoretical lower limit for the clinical SRS data; further investigation is required to
confirm this. R50%Analytic could provide useful guidance for what might be achiev-
able in SRS planning.
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1 | INTRODUCTION
A cranial stereotactic radiosurgery (SRS) plan should be highly con-
formal and have the steepest possible dose gradient outside of the
planning target volume (PTV) to reduce complications associated
with excessive radiation delivered to normal brain tissues as mea-
sured by the volume receiving 12 Gy1 or other intermediate dose
threshold. Several dose gradient metrics have been designed to
quantify the intermediate dose spill outside the PTV. These include
gradient index (GI), gradient measure (GM), and R50%.2–4 The value
of a given intermediate dose spill metric achievable in a clinical
setting is likely a complex function of the size, shape, and location of
the PTV in the cranium, as well as delivery geometry, treatment
modality, and optimization performance. Based on analyses of clinical
treatment plans, Goldbaum et al. and Ballangrud et al. have provided
guidance on limiting values of the GI in cranial SRS planning utilizing
the known PTV volume (VPTV).
5,6 Knowledge of this limit may be
useful to the treatment planner as it provides a realistic goal to pur-
sue in the optimization.
Wang et al. noted that the original Radiation Therapy Oncology
Group (RTOG) protocols 90-05 and 93-05 make no mention of inter-
mediate dose spill.7 However, the importance of intermediate dose
spill, as measured by GI or R50%, in SRS/SRT plan evaluation is now
widely recognized. Furthermore, two plans can have very similar high
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dose region conformity but have very different intermediate dose
spill. The plan with the larger intermediate dose spill does more dam-
age to surrounding tissue; thus, a smaller GI or R50% would yield
less collateral damage. In this work, we examine the R50% metric to
better understand what limits can be expected for R50% in high
quality SRS/SRT plans.
Guidelines for intermediate dose spill metrics used in treatment
planning tend to be phenomenological constructs, and limits so
obtained are based on observations from large numbers of treatment
plans. We have proposed a model-based approach for the metric
R50% that considers the physical characteristics VPTV and PTV sur-
face area (SAPTV). This approach allows for the derivation of an ana-
lytical form of R50% (R50%Analytic) that is based on physical
principles. It is necessary, however, that this analytical methodology
be validated against clinical data. At least one published study on
cranial SRS does provide the necessary data for a meaningful com-
parison of R50%Analytic to clinical data.
8 Zhao et al. provided clear,
tabulated data for a wide range of PTV volumes from 0.15 to
50.1 cm3. These clinical data sets are used to calculate R50% clinical
values (R50%Clinical), which are directly compared to our predicted
R50%Analytic values in this paper. Note: A list of abbreviations is pro-
vided in the Appendix A.
2 | MATERIALS AND METHODS
2.A | R50%Analytic derivation
Consider a spherical PTV volume, VPTV, surrounded by a spherical
shell that encloses the 50% isodose cloud volume (VIDC50%shell) as
illustrated in Fig. 1. The sum of VPTV and VIDC50%shell is the total vol-
ume encompassed by the 50% isodose cloud (VIDC50%). R50% is
defined as the ratio of the volume of the 50% Isodose Cloud to the








Furthermore, we determined an exact value of VIDC50%shell by
integrating the spherical differential shell volume, 4πr2dr, from r =-
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Given that SAPTV ¼4πr2PTV and combining Eqs. (1) and (2), the
resulting analytical form of R50% can be expressed as:










Equation (3) is a form of R50% for a spherical volume. We iden-
tify the three components within the square brackets of Eq. (3) as
zeroth order, first order, and second order terms, respectively. This
complete expression is an extension of previous work that only used
the zeroth order term and, as expected, significantly improves agree-
ment for smaller PTV volumes.9,10
2.B | Δr determination
One additional requirement of this analytical approach is an estimate
of the dose drop-off to 50% parameter, Δr, which cannot be calcu-
lated from first principles at this time. However, it is possible to
obtain realistic estimates of Δr from treatment planning studies.
Note that Δr is likely different for different treatment modalities (i.e.,
Gamma Knife, Cyber Knife, and SRS capable Linacs) and should be
determined for each technology.
In our spherical model, the dose drop-off parameter Δr is the
value of linear distance from the edge of the PTV to the outer edge
of IDC50%shell as shown in Fig. 1 and is taken as isotropic.
To experimentally determine a value of Δr for the R50%Analytic
calculations, we utilized a treatment planning CT of the IROC SRS
Head Phantom (IROC Houston QA Center, Houston, TX) as the
anthropomorphic phantom model. Nine spherical PTVs were cre-
ated in the center of the cranium with volumes ranging from 0.19
to 44 cm3. Treatment planning was performed on an Eclipse radia-
tion treatment planning system (RTPS) using the photon optimizer
PO v15.6 with a final calculation via the AAA v 15.6 algorithm on
a 1 mm calculation grid size. All plans were created for a Varian
TrueBeam STx with a 120 leaf HD MLC and used volumetric mod-
ulated arc therapy (VMAT, RapidArc) techniques. The delivery
geometry employed in this study to determine Δr used five hemi-
arcs spanning 150° arc angles at five couch angles as shown in
Fig. 2. This geometry is both clinically reasonable and highly con-
formal for a central cranial tumor because it uses nearly a full 2π
solid angle. The prescription for PTVs with a volume ≤ 3 cm3 was
18 Gy in one fraction with 99% of the VPTV receiving the dose;
the prescription for PTVs with a volume > 3 cm3 was 27 Gy in
F I G . 1 . Plane through the center of the spherical volumes. Inner
volume is the planning target volume (PTV). The shaded region is
the spherical shell bounded by the 50% isodose cloud and the PTV
surface area. Δr is the radial thickness of the shell, as well as the
distance of dose drop-off from the edge of the PTV to 50%.
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three fractions with 99% of VPTV receiving the prescription dose
(D99% volumetric prescription). One could also use a percent iso-
dose line (PIDL) prescription to achieve the same volumetric PTV
coverage as one achieves with the volumetric prescription.11 Ulti-
mately, we just need 99% of the PTV volume covered by the pre-
scription dose consistently for all plans that determine Δr such that
CI is very nearly 1.0. Eclipse NTO (Normal Tissue Objective) was
used in conjunction with three dose control shells (inner control
shell, middle control shell, and outer control shell) as described by
Clark et al. to directly limit the dose spill outside the PTV, in accor-
dance with standard clinical practices.12 Alternatively, one could
use other dose limiting shell techniques.13 We sought the minimum
value of Δr one could obtain clinically in ideal circumstances. The
quality of these phantom plans can be seen from the parameters
given in Table 1.
Since a highly noncoplanar delivery geometry coupled with a
spherical PTV was chosen, the resulting dose distribution is reasonably
isotropic and can be assumed spherical. This nearly spherical dose dis-
tribution can be clearly seen in Fig. 3 as the transparent yellow iso-
dose cloud of 50% of the prescription dose (IDC50%) surrounding the
solid orange PTV. This distribution bears a marked similarity to Fig. 1
used in the derivation of R50%Analytic. Thus, it becomes simple to
extract a value of Δr for each phantom PTV as follows:
Δr¼ rIDC50% rPTV (4)
Based on the values of Δr obtained from the phantom study, a
power law fit was generated (Microsoft Excel) for Δr as a function
of VPTV as shown in Fig. 4.
The resulting power law expression for Δr, in units of cm, is:
Δr¼0:2844V0:1973PTV (5)
where VPTV is measured in cm
3.
As can be seen in Table 1, the GM values reported by Eclipse for
these spherical volumes are nearly identical to the Δr values
obtained from Eq. (4). This should not be surprising since GM is
defined as the difference, in centimeters, of the equivalent sphere
radii of VIDC50% and VIDC100% (r50%eq and r100%eq, respectively).
7
Thus,
GM¼ r50%eq r100%eq (6)
By comparison, for a perfectly conformal plan (CI = 1.0),
VIDC100% is identical to and spatially coincident with VPTV. Thus, for
F I G . 2 . The five hemi-arcs beam arrangement for determination of
Δr. This three-dimensional (3D) view of the IROC head phantom
shows the beam delivery geometry used for the phantom plans used
to determine Δr for a series of nine spherical planning target
volumes. Each red curve in the figure represents the path of an arc
around the cranium using the Varian IEC scale. For couch angles
355° (A), 315° (B), and 270° (C), the arcs span 195° to 345°. For
couch angles 45° (D) and 5° (E), the arcs span 15° to 165°.
TAB L E 1 Summary of treatment planning properties obtained from the IROC SRS head phantom study to determine the value of Δr.
VPTV (cm
3) rPTV (cm) CIRTOG HIRTOG GM (cm) rIDC50% (cm) Δr (cm) PIDL
0.19 0.36 1.18 1.80 0.20 0.57 0.22 57.3
0.55 0.51 0.99 1.26 0.25 0.76 0.25 80.8
0.99 0.62 1.04 1.38 0.27 0.90 0.28 72.8
1.96 0.78 1.04 1.36 0.30 1.09 0.31 83.2
2.96 0.89 1.03 1.31 0.34 1.23 0.34 78.5
3.97 0.98 1.04 1.27 0.35 1.34 0.36 79.6
6.93 1.18 0.99 1.22 0.40 1.58 0.40 85.4
20.45 1.70 0.99 1.21 0.52 2.22 0.52 88.7
43.99 2.19 0.99 1.21 0.65 2.83 0.64 91.7
Ave CIRTOG 1.03
Std Dev 0.06
CIRTOG is the conformity index, and HIRTOG is the homogeneity index. All plans are normalized volumetrically to D99% (99% of the PTV volume receives
100% of the prescription dose). The equivalent PIDL is determined by matching the coverage of the D99% prescription. Δr values are calculated from
the difference of rIDC50% and rPTV, assuming both volumes are spherical. Note the Eclipse GM values are nearly identical to Δr.
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a spherical PTV, r100%eq = rPTV. Furthermore, if IDC50% is assumed
to be spherical, r50%eq = rIDC50%. Therefore, it is reasonable to
assume that for nearly spherical volumes, the GM values obtained
from Eclipse can be considered equivalent to Δr. For simplicity, Δr
was only considered as a function of VPTV.
2.C | Comparison methodology
To validate the clinical relevancy of R50%Analytic, we compared val-
ues generated from Eq. (3) to R50%Clinical values obtained from a
published data set. Zhao et al. performed a retrospective analysis
of 30 clinical cases and investigated an optimal prescription isodose
line that yields the steepest dose fall-off (smallest GI) outside the
PTV for cranial SRS plans. While R50% values are not directly
presented in the retrospective analysis, clinical values for GI and
CIRTOG values are given for all 30 cases. Given the following defini-














Using this approach, the data of Zhao et al. will yield the equiva-
lent R50% to be used for comparison.
3 | RESULTS
Table 2 contains VPTV, CIRTOG, and GI values directly transcribed
from Zhao et al., values calculated from the clinical data, and the
subsequently generated R50%Analytic values. The parameter rPTV was
calculated using an assumption that PTV is spherical, and thus, it is
an equivalent sphere radius of the PTV. SAPTV is the surface area of
the equivalent sphere PTV. R50%Clinical was obtained by multiplying
the clinical CIRTOG and GI values provided by Zhao et al. [Eq. (9)].
Table 2 also displays the %Difference between the values of
R50%Clinical and R50%Analytic. R50%Analytic values are uniformly smal-
ler than R50%Clinical values by an average of 15%  7%. A quick
observation confirms that for smaller PTV volumes the R50%Clinical
values are significantly larger than the R50%Analytic results obtained
from Eq. (3). As an example, for the smallest PTV volume (0.15 cm3),
R50%Clinical is 34.3% larger than R50%Analytic. These data are also
shown graphically in Fig. 5, which indicates the larger R50%Clinical
values over the PTV volume range included in this study.
4 | DISCUSSION
It can be readily seen that R50%Analytic values are consistently lower
than the corresponding R50%Clinical data (Fig. 5). Consideration of
F I G . 3 . Typical results for the phantom study to determine Δr. The diagram shows an AP DRR and a right lateral DRR that display the
position and size of the PTV (solid orange shape) and IDC50% (transparent yellow shape) within the cranium. The distance from the edge of
the PTV and the outer edge of IDC50% is Δr. The volume of the PTV is 3 cm3. Note that the IDC50% is very nearly spherical.
F I G . 4 . Phantom study derived Δr as a function of VPTV. A good
fit is obtained with the power law function shown.
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the treatment planning conditions of Zhao et al. may provide a basis
for a reasonable explanation of the differences observed. The clinical
data presented by Zhao et al. are a composite of situations influ-
enced by a wide range of conditions: unique prescription doses,
diverse sizes and shapes, various locations in the brain, and variable
proximity to different organs at risk among other restrictions. The
distance of dose drop-off from PTV surface to 50% (Δr) is likely
affected by some of these conditions. In contrast, consider the ideal
conditions assumed in the derivation of Eq. (3). For simplicity, isotro-
pic dose drop-offs from PTV surface to 50% were assumed around
spherical PTVs, which implies a 4π delivery geometry. In most realis-
tic scenarios, the treatment of cranial targets can achieve a 2π
delivery geometry for a Linac-based SRS delivery. Clinical PTVs,
however, are not ideal spheres, and dose drop-offs are not perfectly
isotropic around the PTV. Also, clinical considerations of organs at
risk in proximity of the PTV were not included in the R50%Analytic
model. As a result, the R50%Analytic model, as indicated by Eq. (3),
should be considered as a theoretical lower limit of R50% for
intracranial targets.
We measured Δr in a simple planning study of spherical targets
of varying volumes. Our planning study used VMAT (RapidArc) deliv-
ery. A similar study could be done to determine Δr using dynamic
conformal arc therapy (DCAT), and the values of Δr so obtained
could be different. The data provided by Zhao et al. for the replan






(b) Δr (cm) R50%Analytic %Diff of R50% Values
0.15 0.33 1.37 1.59 3.87 6.15 0.20 4.05 −34.26
0.21 0.37 1.71 1.30 3.50 4.55 0.21 3.85 −15.47
0.37 0.45 2.49 1.61 3.14 5.06 0.23 3.54 −29.88
0.44 0.47 2.80 1.27 3.07 3.90 0.24 3.46 −11.25
0.48 0.49 2.96 1.30 3.19 4.15 0.25 3.42 −17.55
0.53 0.50 3.17 1.32 3.06 4.04 0.25 3.37 −16.49
0.61 0.53 3.48 1.23 3.00 3.69 0.26 3.31 −10.31
0.75 0.56 3.99 1.24 2.90 3.60 0.27 3.22 −10.46
1.30 0.68 5.76 1.21 2.75 3.33 0.30 3.00 −9.83
1.80 0.75 7.15 1.33 2.76 3.67 0.32 2.88 −21.48
2.10 0.79 7.93 1.25 2.62 3.28 0.33 2.83 −13.61
2.60 0.85 9.14 1.28 2.70 3.46 0.34 2.76 −20.18
3.10 0.90 10.28 1.14 2.57 2.93 0.36 2.70 −7.74
4.20 1.00 12.59 1.08 2.51 2.71 0.38 2.61 −3.67
4.70 1.04 13.57 1.20 2.48 2.98 0.39 2.58 −13.34
4.80 1.05 13.76 1.22 2.55 3.11 0.39 2.57 −17.29
6.10 1.13 16.14 1.15 2.41 2.77 0.41 2.51 −9.56
6.90 1.18 17.52 1.15 2.47 2.84 0.42 2.47 −12.91
7.30 1.20 18.20 1.16 2.48 2.88 0.42 2.46 −14.52
7.80 1.23 19.02 1.16 2.45 2.84 0.43 2.44 −14.08
9.50 1.31 21.69 1.22 2.68 3.27 0.44 2.39 −26.83
11.40 1.40 24.49 1.05 2.39 2.51 0.46 2.35 −6.42
12.60 1.44 26.18 1.11 2.44 2.71 0.47 2.32 −14.16
14.10 1.50 28.22 1.06 2.39 2.53 0.48 2.30 −9.25
18.80 1.65 34.19 1.12 2.36 2.64 0.51 2.24 −15.43
21.30 1.72 37.15 1.14 2.42 2.76 0.52 2.21 −19.93
27.30 1.87 43.84 1.27 2.13 2.71 0.55 2.16 −20.21
34.40 2.02 51.14 1.07 2.31 2.47 0.57 2.11 −14.50
41.70 2.15 58.14 1.06 2.29 2.43 0.59 2.08 −14.42
50.10 2.29 65.71 1.07 2.24 2.40 0.62 2.04 −14.71
Ave %Diff −15.32
Std Dev 6.63
Values shown are actual and calculated parameters from Zhao et. al. SAPTV values were calculated assuming spherical PTVs in the Zhao et al. data. Also
shown are values of Δr and R50%Analytic obtained from Eqs. (4) and (3), respectively. (a)values given by Zhao et al. (b)values calculated from Zhao et al.
(c)value calculated from Zhao et al. based on spherical PTV assumption.
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of clinical cases were done using DCAT delivery. If the Δr was larger
as a function of VPTV using DCAT delivery, the agreement with the
data provided by Zhao et al. would improve. However, our goal in
this work was to provide the minimum achievable R50% as
described by R50%Analytic. We chose to determine Δr using VMAT
techniques because VMAT delivery of SRS/SRT is rapidly gaining
popularity, particularly for multiple target cases.6,11
There are other ways to measure or estimate Δr and similar
quantities. We used a simple planning study and the GM functional-
ity built into Eclipse. Sung and Choi use proprietary software to
determine cumulative dose gradient index (cDGI), a metric of their
creation similar to Δr in the case of the cDGI for the 50% of pre-
scription dose (cDGI50%).14 They determine the cDGI50% for a
3 cm diameter spherical target (VPTV = 14.14 cm
3) to be cDGI50% =
5.98 mm. Our empirical formula for Δr [Eq. (5)] for that same vol-
ume yields Δr = 4.80 mm, which is comparable to the value of
cDGI50%. R50%Analytic will be a larger value if one uses cDGI50% as
the estimate for Δr. Zhang et al. propose yet another novel metric
they call dose-dropping speed (DDS).15 Dose-dropping speed cer-
tainly has relationship to Δr and shows similar dependence on VPTV,
which they describe in terms of PTV diameter. In fact, to compare
values for 1/DDS to our Δr values, one finds they are within 0.1 mm
for a 0.9 cm3 target and within 1.4 mm for a 61.6 cm3 target, with
the Zhang et al. determined values of 1/DDS being the larger values.
In our work, we do not propose a new metric but rather a way
to predict the minimum value of an established metric, R50%, for an
SRS/SRT case based on three parameters: VPTV, SAPTV, and Δr.
Because Δr cannot be calculated from first principles at this time,
we measure Δr for the case of spherical targets. Yet, the value of Δr
is not the primary focus of this work. Our primary focus is testing
the equation R50%Analytic against the clinical data provided by Zhao
et al.
Goldbaum et al. noted that a group of plans with very similar
PTV volumes produced a wide range of R50% values. They hypothe-
sized that the increase in R50% could be related to variations in
SAPTV but were not able to quantify the relationship. Although this
current study only considered spherical volumes, the dependence on
SAPTV is explicit in Eq. (3), and conceptually, this analytic model
should be able to account for variations in SAPTV. In fact, the model
would predict larger R50% values for targets with increased SAPTV
to VPTV ratios, which is consistent with the suppositions in Gold-
baum et al. In previous work, it was quantitatively shown that an
increase in the SAPTV to VPTV ratio leads to an increase in R50% val-
ues.9 For any given volume, the shape that corresponds to the small-
est surface area is a sphere,16 and the assumption of a spherical PTV
with an isotropic dose drop-off is central to the construction of our
analytic equation for R50% [Eq. (3)]. This reflects an ideal case, and
therefore, it would be reasonable to argue that the analytical equa-
tion yields the smallest possible R50% (the R50% lower limit). Zhao
et al. provided VPTV values for their study but did not provide SAPTV
data. However, this is not unexpected since commercial treatment
planning systems do not include surface area as part of the structure
statistics as they report (like VPTV). Without available surface area
information, we assumed a spherical PTV (smallest surface area) and
calculated SAPTV from the provided VPTV values; the calculated
SAPTV values were then used in Eq. (3) to generate R50%Analytic. The
actual clinical PTV shapes in the data of Zhao et al. are likely to have
some nonspherical character.
At lower VPTV values, a larger difference is seen between
R50%Clinical and R50%Analytic (Fig. 5), which indicates that caution
should be taken when evaluating clinical values of R50% at low PTV
volumes. Zhao et al. suggested that, for small PTV volumes, dose
drop-off is extremely sensitive to location, target shape, and beam
settings and discussed the limitation of treatment planning systems
to accurately compute dose for small targets. Our analytic form does
not suffer from those clinical and technical challenges, and thus, it is
a reasonable assumption that, for a certain VPTV, the smallest theo-
retical R50% value is expressed by Eq. (3). This prediction could be
used as a guide for the treatment planner to consider, among other
factors, when progressing through the plan optimization. A set of
PTVs of a given volume could have different shapes and, thus, dif-
ferent surface areas. Equation (3) clearly shows that a larger surface
area PTV should have a larger R50%. As such, knowing the SAPTV
and recognizing that a larger surface area guarantees a higher R50%
value can be useful at the onset of the treatment planning process.
Based on the comparison results with Zhao et al., a plan with R50%
within 15% of the R50%Analytic would be a plan with excellent inter-
mediate dose spill.
It is possible that R50%Analytic could be used for automated plan-
ning or artificial intelligence planning systems that seek to control
intermediate dose spill.13 As such, R50%Analytic would be used as the
F I G . 5 . Comparison of R50%Clinical and R50%Analytic as functions of
the VPTV in the range from 0.15 to 50.1 cm
3. This is a graphical
representation of the data in Table 2. The R50%Clinical values are
extracted from the clinical study of Zhao et al. The values of
R50%Analytic are calculated from Eq. (3). Note that the general trend
of R50%Clinical as a function of VPTV is reflected in the same trend of
R50%Analytic. Furthermore, the R50%Clinical values are consistently
larger than the R50%Analytic values.
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target or goal R50% of the automated planning. R50%Analytic, as
expressed in Eq. (3), may not be achievable in all circumstances, but
as stated above, a plan within 15% of the R50%Analytic is a plan
with excellent intermediate dose spill.
Understanding intermediate dose spill when multiple PTVs are
optimized simultaneously using a single isocenter is not a trivial task.
It depends on several factors: relative locations and sizes of PTVs
with respect to one another (e.g., a large PTV in close proximity to a
much smaller PTV), plan delivery geometry, plan optimization perfor-
mance, etc. There is no easy or straight forward way to account for
an increase in R50% of a PTV due to its location with respect to
another PTV. Drawing from comments of Bohoudi et al. and Gold-
baum et al. stating that their results obtained for intermediate dose
spill around single cranial targets should apply to multiple cranial tar-
get cases as well,5,17 we expect R50%Analytic to perform well in pre-
dicting the theoretical minimum R50% for individual PTVs in multiple
target cranial SRS/SRT cases. This will need to be confirmed by fur-
ther investigation.
5 | CONCLUSION
An analytical expression for R50% was derived for the special case
of spherical volumes. The expression appears to provide a lower limit
of R50% when compared to peer-reviewed, clinical data. We surmise
that SAPTV plays an important role in the determination of the R50%
value ultimately achievable in treatment planning. Further research is
needed to establish the role of SAPTV for other PTV shapes in the
determination of treatment planning outcomes. Research is also
needed to establish methods for obtaining Δr and investigate addi-
tional determining factors beyond VPTV.
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APPENDIX A
ABBREVIATIONS
Table A1 contains definitions for abbreviations used throughout this
article.
TAB L E A1 List of abbreviations with definitions.
Abbreviation Definition
cDGI Cumulative dose gradient index
CIRTOG RTOG conformity index




HIRTOG RTOG homogeneity index
IDC Isodose cloud
IDC50% 50% (of prescription dose) isodose cloud
IDC50%shell Distance from the edge of the planning target volume to the edge of the 50% isodose cloud
IDC100% 100% (of prescription dose) isodose cloud
NTO Normal tissue objective; Instructs the optimizer to limit dose to non-target volumes
OAR Organs at risk
PIDL Prescription isodose line
PTV Planning target volume
Δr Distance of dose drop-off from the edge of the planning target volume to 50% dose
rIDC50% Radius of the 50% isodose cloud
rPTV Radius of the planning target volume
r50%eq Equivalent sphere radius of the volume of the 50% isodose cloud
r100%eq Equivalent sphere radius of the volume of the 100% isodose cloud
R50% Ratio of the volume of the 50% isodose cloud to the volume of the planning target volume
R50%Analytic Value of R50% generated from our analytical expression
R50%Clinical Value of R50% calculated from clinical data
RTPS Radiation treatment planning system
SAPTV Surface area of the planning target volume
SRS Stereotactic radiosurgery
SRT Stereotactic radiotherapy
VIDC50% Volume of the 50% isodose cloud
VIDC50%shell Volume of the 50% isodose cloud minus the volume of the planning target volume
VIDC100% Volume of the 100% isodose cloud
VPTV Volume of the planning target volume
VMAT Volumetric modulated arc therapy
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